Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49,633,071
-
Number of holders
-
137
-
Total 13F shares, excl. options
-
35,195,489
-
Shares change
-
-455,628
-
Total reported value, excl. options
-
$716,303,054
-
Value change
-
-$227,829,815
-
Put/Call ratio
-
191%
-
Number of buys
-
67
-
Number of sells
-
-90
-
Price
-
$20.35
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q4 2018
198 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q4 2018.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 137 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35,195,489 shares
of 49,633,071 outstanding shares and own 71% of the company stock.
Largest 10 shareholders include STATE STREET CORP (2,859,610 shares), Vanguard Group Inc (2,794,737 shares), BlackRock Inc. (2,665,886 shares), ORBIMED ADVISORS LLC (2,598,883 shares), JANUS HENDERSON GROUP PLC (1,861,944 shares), FEDERATED INVESTORS INC /PA/ (1,528,900 shares), GREAT POINT PARTNERS LLC (1,379,700 shares), Sarissa Capital Management LP (1,343,000 shares), MILLENNIUM MANAGEMENT LLC (1,332,696 shares), and Camber Capital Management LP (1,300,000 shares).
This table shows the top 137 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.